Femoral Artery News and Research

RSS

FDA's Circulatory System Devices Panel unanimously recommends Cook Medical's Zilver PTX Drug-Eluting Stent

The Zilver PTX Drug-Eluting Stent, the first device of its kind developed to treat peripheral artery disease (PAD) in the superficial femoral artery (SFA), has received a unanimous recommendation from the Food and Drug Administration's (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee, Cook Medical announced today.

14 Oct 2011

TCT to showcase major scientific research breakthroughs in cardiovascular medicine

The Cardiovascular Research Foundation has announced the late breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2011 scientific symposium. Presented in partnership with the American College of Cardiology (ACC), TCT 2011 is the world's leading educational meeting specializing in interventional cardiovascular medicine and will take place November 7-11, 2011 in San Francisco.

16 Sep 2011

CRF announces late breaking trials & first report investigations to be presented at TCT 2011

The Cardiovascular Research Foundation has announced the late breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2011 scientific symposium. Presented in partnership with the American College of Cardiology (ACC), TCT 2011 is the world’s leading educational meeting specializing in interventional cardiovascular medicine and will take place November 7-11, 2011 in San Francisco.

15 Sep 2011

Angioslide introduces new 5x300mm PROTEUS device for treating Superficial Femoral Artery

Angioslide Ltd. announces the first procedures with its new 5x300mm PROTEUS device for treating the Superficial Femoral Artery. PROTEUS technology combines a Percutaneous Transluminal Angioplasty balloon and embolic capture of particles in one device. The new 5x300 mm size joins Angioslide's current dedicated product line solutions for the lower limbs.

8 Sep 2011

Transradial cardiac catheterizations reduce complications, increase patient comfort

Each year, more than one million cardiac catheterizations are performed in the United States, and most of these procedures are performed through the groin to access the arteries that provide blood supply to the heart.

25 Aug 2011

First renal denervation with Medtronic Symplicity Catheter System performed in Latin America

Medtronic today announced the first use in Latin America of renal denervation with the Medtronic Symplicity Catheter System™ to treat a patient with resistant hypertension, which is defined as high blood pressure despite treatment with three or more anti-hypertensive medications. Hypertension is an especially dangerous disease affecting hundreds of millions of people worldwide.

From Medtronic 10 Aug 2011

FDA approves protocol for Medtronic's SYMPLICITY HTN-3 for treatment of hypertension

Medtronic, Inc., announced today that the U.S. Food and Drug Administration (FDA) has conditionally approved the protocol for SYMPLICITY HTN-3, the company's U.S. clinical trial of renal denervation with the Symplicity Catheter System for the treatment of resistant hypertension, an especially dangerous disease affecting hundreds of millions of people worldwide.

From Medtronic 12 Jul 2011

Transcatheter valve replacement safe and effective alternative to open-heart surgery

An innovative approach for implanting a new aortic heart valve without open-heart surgery is being offered at Rush University Medical Center to patients with severe aortic stenosis who are at high-risk or not suitable candidates for open heart valve replacement surgery.

27 Jun 2011

Zilver PTX stent more effective than PTA for treatment of femoral artery lesions

Results of a prospective, randomized trial indicate that when treating femoral artery (SFA) lesions, the Zilver PTX Paclitaxel-Eluting Stent shows sustained effectiveness compared to percutaneous transluminal angioplasty, even in diabetic patients.

20 Jun 2011

Heart function may be affected in people with Type 2 diabetes as early as adolescence

Heart function may be affected in people with Type 2 diabetes as early as adolescence, according to a new study that will be presented Sunday at The Endocrine Society's 93rd Annual Meeting in Boston.

8 Jun 2011

First human implant of St. Jude Medical's Portico transcatheter aortic heart valve

St. Jude Medical, Inc., a global medical device company, today announced the first human implant of its Portico transcatheter aortic heart valve. The procedure was performed by Dr. John Webb, director of cardiac catheterization and interventional cardiology at St. Paul's Hospital in Vancouver, British Columbia.

7 Jun 2011

FDA grants Pathway marketing clearance for JETSTREAM Navitus revascularization catheter for PVD

Pathway Medical Technologies, Inc, an innovator of endovascular treatments for peripheral vascular disease (PVD), announced today that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) clearance to market JETSTREAM Navitus, an enhanced revascularization catheter for the treatment of PVD.

6 Jun 2011

IDEV completes enrollment in SUPERA stent trial for treatment of peripheral artery disease

IDEV Technologies, Inc. today announced the completion of enrollment in the SUPERB Trial, an FDA-approved IDE trial evaluating the use of IDEV's SUPERA stent system for treatment of peripheral artery disease in the superficial femoral artery.

3 Jun 2011

Medtronic issues statement on results of CoreValve System clinical data presented at EuroPCR 2011

Medtronic, Inc. today issued a statement on results of clinical data presented at EuroPCR 2011 that show the Medtronic CoreValve System, delivered through a new approach beneath the collarbone, achieved excellent procedural success rates and low in-hospital complication rates.

From Medtronic 19 May 2011

Medtronic to present new clinical results on innovative medical devices at EuroPCR

New clinical data on a range of innovative medical devices from Medtronic, Inc., to treat cardiac and vascular diseases - from severe aortic stenosis and uncontrolled hypertension, to coronary and peripheral artery disease - will be presented next week at EuroPCR. Many of the presentations will be featured during late-breaking sessions at this large international interventional cardiology meeting, which takes place in Paris from May 17-20.

From Medtronic 12 May 2011

Boston Scientific initiates clinical enrollment for INNOVA Self-Expanding Bare-Metal Stent System trial

Boston Scientific Corporation today announced the start of patient enrollment in the SuperNOVA clinical trial, an international, prospective, single-arm, non-randomized trial evaluating the safety and effectiveness of the INNOVA™ Self-Expanding Bare-Metal Stent System in patients with stenosis of the superficial femoral artery (SFA) or proximal popliteal artery (PPA).

6 Apr 2011

Less-invasive catheter-based aortic valve replacement as safe and effective as open surgery

Less-invasive catheter-based aortic valve replacement has a similar one-year survival as open valve-replacement surgery for patients at high risk for surgery.

5 Apr 2011

SMT announces $10.5 million financing to develop novel device for use in TAVI procedures

SMT Research and Development Ltd. of Herzliya Pituach, Israel announced today a significant investment by OrbiMed Advisors LLC. SMT is finalizing the development of a novel embolic protection device designed for use during Transcatheter Aortic Valve Implantation procedures.

4 Apr 2011

Prostatic artery embolization comparable to transurethral resection

A new interventional radiology treatment that blocks blood supply to men's enlarged prostate glands shows comparable clinical results to transurethral resection of the prostate (or TURP), considered the gold standard (or most common) treatment. However, this minimally invasive treatment-prostatic artery embolization-has none of the risks associated with TURP, such as sexual dysfunction, urinary incontinence, blood loss and retrograde ejaculation, noted researchers at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago.

30 Mar 2011

First clinical use of GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface on lower profile delivery system

W. L. Gore & Associates (Gore) today reported the first clinical use in the U.S. of the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface on a lower profile delivery system. The GORE VIABAHN Device is designed to percutaneously treat Superficial Femoral Artery (SFA) and iliac peripheral artery disease by relining the native vessel.

21 Mar 2011